- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02931747
Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student
August 15, 2017 updated by: Jintanaporn Wattanathorn, Khon Kaen University
The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.
Study Overview
Status
Completed
Conditions
Detailed Description
Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study.
The consumption of brain booster product or functional food for improving memory has gained much attention.
It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential.
Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Khon Kaen, Thailand, 40002
- Jitanaporn Wattanathorn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years to 14 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province.
- Body mass index is between 18.5-24.9
Exclusion Criteria:
- Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded.
- Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded.
- Alcohol addict or smoking addiction (more than 10 pieces/day)
- Athlete or subjects who have a regular exercise more than 3 times/week
- Subjects who don't follow the instruction during the trial
- Subjects who are participating the other project.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
|
Subjects are received Placebo once daily for 16 weeks.
|
|
Active Comparator: Bacopa Monnieri 300 mg/day
Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
|
Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
|
|
Active Comparator: Bacopa Monnieri 600 mg/day
Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
|
Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive processing using the latency of P300 wave
Time Frame: 4 months
|
The latency of P300 wave was measured and expressed as millisecond.
|
4 months
|
|
Cognitive processing using the amplitude of P300 wave
Time Frame: 4 months
|
The amplitude of P300 wave was measured and expressed as micro-volt.
|
4 months
|
|
Attention using the latency of N100 wave
Time Frame: 4 months
|
The latency of N100 wave was measured and expressed as millisecond.
|
4 months
|
|
Attention using the amplitude of N100 wave
Time Frame: 4 months
|
The amplitude of N100 wave was measured and expressed as micro-volt.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of working memory using computerized battery test
Time Frame: 4 months
|
The accuracy of working memory was determined and expressed as percentage.
|
4 months
|
|
Speed of working memory using computerized battery test
Time Frame: 4 months
|
The speed of working memory was determined and expressed as millisecond.
|
4 months
|
|
Assessment of psychiatric symptoms using the symptom check list 90 (SCL-90)
Time Frame: 4 months
|
4 months
|
|
|
Assessment of mood scale using Bond-Lader visual analogue scales
Time Frame: 4 months
|
4 months
|
|
|
Acetylcholinesterase activity in serum
Time Frame: 4 months
|
4 months
|
|
|
Monoamine oxidase activity in serum
Time Frame: 4 months
|
4 months
|
|
|
Glutamic acid decarboxylase (GAD) activity in serum
Time Frame: 4 months
|
4 months
|
|
|
Gamma-aminobutyric acid (GABA)-transaminase in serum
Time Frame: 4 months
|
4 months
|
|
|
Malondialdehyde level in serum
Time Frame: 4 months
|
4 months
|
|
|
Activity of superoxide dismutase in serum
Time Frame: 4 month
|
4 month
|
|
|
Activity of catalase in serum
Time Frame: 4 month
|
4 month
|
|
|
Activity of glutathione peroxidase in serum
Time Frame: 4 month
|
4 month
|
|
|
Consumption safety of Bacopa Monnieri using electrocardiogram (EKG)
Time Frame: 4 month
|
4 month
|
|
|
Consumption safety of Bacopa Monnieri using hematological values .
Time Frame: 4 month
|
The hematological values including red blood cell, white blood cell, hematocrit and platelet were determined and the data was expressed as number of subject presented with abnormal hematological value.
|
4 month
|
|
Consumption safety of Bacopa Monnieri using blood chemistry
Time Frame: 4 month
|
The blood chemistry values including renal function test, liver function test, lipid profile, electrolytes and glucose were determined and the data was expressed as number of subject presented with abnormal blood chemistry value.
|
4 month
|
|
Consumption safety of Bacopa Monnieri using blood pressure measurement
Time Frame: 4 month
|
4 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
March 1, 2017
Study Registration Dates
First Submitted
October 8, 2016
First Submitted That Met QC Criteria
October 11, 2016
First Posted (Estimate)
October 13, 2016
Study Record Updates
Last Update Posted (Actual)
August 18, 2017
Last Update Submitted That Met QC Criteria
August 15, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- HE581418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
RAGE BioRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of